Bibliografía del artículo
1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-34, 1988.
2. Hennekens CH, Knatterud GL, Pfeffer MA. Use of aspirin to reduce risks of carciovascular disease in patients with diabetes. Diabetes Care 27:2752-4, 2004.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-97, 2001.
4. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 324:939-42, 2002.
5. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-16, 2003.
6. Lee CD, Folsom AR, Pankow JS, Brancati FL. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 109:855-60, 2004.
7. Sobel BE. Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 120(Suppl. 2):S3-11, 2007.
8. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 67:997-1026, 2007.
9. Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC). Adaptación española de la Guía europea de prevención cardiovascular. Rev Esp Salud Pública 78:435-8, 2004.
10. Grupo para el Estudio de la Diabetes en Atención Primaria (Gedaps), Sociedad Española de Cardiología (SEC), Sociedad Española de Diabetes (SED), Sociedad Española de Medicina Interna (SEMI). Documento 2005 de consenso entre varias sociedades científicas sobre pautas de manejo del paciente tipo 2 en España. Abordaje de otros factores de riesgo cardiovascular. Av Diabetol 21(Suppl.1):S34-44, 2005.
11. Tercer grupo de trabajo de las Sociedades Europeas y otras Sociedades sobre Prevención Cardiovascular en la Práctica Clínica. Guía europea de prevención cardiovascular en la práctica clínica. Rev Esp Salud Pública 78:439-56, 2004.
12. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:234-64, 2004.
13. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136:157-160, 2002.
14. Pearson TA, Blair SN, Daniels SR, et al. American Heart Association Science Advisory and Coordinating Committee. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388-391, 2002.
15. American Diabetes Association. Executive summary: Standards of medical care in diabetes - 2008. Diabetes Care 31(Suppl. 1):S5-11, 2008.
16. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 27(Suppl. 1):S72-3, 2004.
17. Steering Committee for the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321:129-35, 1989.
18. The ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study. Report 14. JAMA 268:1292-300, 1992.
19. Hansson L, Zanchetti A, Carruthers SG; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351:1755-62, 1998.
20. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002.
21. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown D. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA 295:306-13, 2006.
22. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296:313-6, 1988.
23. Medical Research Council. Thrombosis Prevention Trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233-41, 1998.
24. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357:89-95, 2001.
25. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293-304, 2005.
26. Sacco M, Pellegrini F, Roncaglioni MC. The PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264-72, 2003.
27. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) -its relation to metabolic control. Thromb Res 113:97-9, 2004.
28. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99-103, 2005.
29. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567-70, 2006.
30. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-17, 2006.
31. Wang TH, Bhatt DL, Fox KAA, Steinhubl SR, Brennan DM, Hacke W, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 28:2200-7, 2007.
32. Japanese primary prevention of atherosclerosis with aspirin for diabetes (JPAD) trial. Disponible en http://clinicaltrials.gov/show/NCT00110448.
33. Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 117:459-68, 2004.
34. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G; ACCEPT-D Study Group. Aspirin and simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8(21), 2007. Disponible en www.trialsjournal.com/contents/B/1/21.
35. Maciá Bobes C, Macías Robles MD, Ronzón Fernández A, Botas Cervero P, López Díaz MV, Municio Heras AI. Hemorragia suprarrenal unilateral asociada a crisis hipertensiva en un paciente antiagregado. Arch Esp Urol 60:1119-22, 2007.
36. Hennekens CH, Schor K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 110:1706-8, 2004.
37. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An update on the primary prevention of cardiovascular disease. Arch Intern Med 163:2006-10, 2003.
38. Ambrosi P, Villani P, Bouvenor G. Antiplatelet therapy for primary prevention in diabetes. Diabetes Metab 32(Suppl. 2):S52-6, 2006.
39. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28:1925-7, 2007.
40. Sheen AJ, Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus. Eur Heart J 27:2900, 2006.
41. Maciá Bobes C, Ronzón Fernández A, Fernández García E. La prevención primaria con aspirina de las enfermedades cardiovasculares en personas diabéticas. Revisión de las pruebas disponibles. Rev Esp Salud Pública 80:613-20, 2006.
42. Morimoto T, Nakayama M, Saito Y, Ogawa H. Aspirin for primary prevention of atherosclerotic disease in Japan. J Atheroscler Thromb 14:159-166, 2007.